<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Saunders MN</submitter><funding>National Institute of Allergy and Infectious Diseases</funding><funding>NIAID NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>e2400237</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11527797</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(5)</volume><pubmed_abstract>Food allergy is a prevalent, potentially deadly disease caused by inadvertent sensitization to benign food antigens. Pathogenic Th2 cells are a major driver for disease, and allergen-specific immunotherapies (AIT) aim to increase the allergen threshold required to elicit severe allergic symptoms. However, the majority of AIT approaches require lengthy treatments and convey transient disease suppression, likely due to insufficient targeting of pathogenic Th2 responses. Here, the ability of allergen-encapsulating nanoparticles to directly suppress pathogenic Th2 responses and reactivity is investigated in a mouse model of food allergy. NPs associate with pro-tolerogenic antigen presenting cells, provoking accumulation of antigen-specific, functionally suppressive regulatory T cells in the sm</pubmed_abstract><journal>Advanced healthcare materials</journal><pubmed_title>Allergen-Encapsulating Nanoparticles Reprogram Pathogenic Allergen-Specific Th2 Cells to Suppress Food Allergy.</pubmed_title><pmcid>PMC11527797</pmcid><funding_grant_id>R01 AI155678</funding_grant_id><funding_grant_id>R01 AI148076</funding_grant_id><funding_grant_id>T32GM007863</funding_grant_id><funding_grant_id>R01AI155678</funding_grant_id><funding_grant_id>T32 GM007863</funding_grant_id><pubmed_authors>Quiros M</pubmed_authors><pubmed_authors>Chiang MY</pubmed_authors><pubmed_authors>Landers JJ</pubmed_authors><pubmed_authors>Podojil JR</pubmed_authors><pubmed_authors>Miller SD</pubmed_authors><pubmed_authors>Bealer EJ</pubmed_authors><pubmed_authors>Crumley K</pubmed_authors><pubmed_authors>Hocevar SE</pubmed_authors><pubmed_authors>O'Konek JJ</pubmed_authors><pubmed_authors>Parkos CA</pubmed_authors><pubmed_authors>Ross BC</pubmed_authors><pubmed_authors>Urie RR</pubmed_authors><pubmed_authors>Williams LA</pubmed_authors><pubmed_authors>Benson OE</pubmed_authors><pubmed_authors>Nusrat A</pubmed_authors><pubmed_authors>Saunders MN</pubmed_authors><pubmed_authors>Rad LM</pubmed_authors><pubmed_authors>Janczak KW</pubmed_authors><pubmed_authors>Shea LD</pubmed_authors><pubmed_authors>Angadi AR</pubmed_authors><pubmed_authors>Griffin KV</pubmed_authors></additional><is_claimable>false</is_claimable><name>Allergen-Encapsulating Nanoparticles Reprogram Pathogenic Allergen-Specific Th2 Cells to Suppress Food Allergy.</name><description>Food allergy is a prevalent, potentially deadly disease caused by inadvertent sensitization to benign food antigens. Pathogenic Th2 cells are a major driver for disease, and allergen-specific immunotherapies (AIT) aim to increase the allergen threshold required to elicit severe allergic symptoms. However, the majority of AIT approaches require lengthy treatments and convey transient disease suppression, likely due to insufficient targeting of pathogenic Th2 responses. Here, the ability of allergen-encapsulating nanoparticles to directly suppress pathogenic Th2 responses and reactivity is investigated in a mouse model of food allergy. NPs associate with pro-tolerogenic antigen presenting cells, provoking accumulation of antigen-specific, functionally suppressive regulatory T cells in the sm</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2026-06-06T23:31:14.592Z</modification><creation>2025-04-06T13:59:47.827Z</creation></dates><accession>S-EPMC11527797</accession><cross_references><pubmed>38691819</pubmed><doi>10.1002/adhm.202400237</doi></cross_references></HashMap>